ABPI Chief Executive Stephen Whitehead has welcomed the publication of a ground-breaking new UK NHS Medicines Bill projection by the Office of Health Economics (OHE) published in Pharmaeconomics. This study corrects common misconceptions by clearly showing that NHS spending on medicines is under control.
30 September, 2013
A novel drug for patients with brain cancer, 2B3-101, has shown preliminary positive results. The Dutch biotech to-BBB has developed 2B3-101 and initiated a clinical trial to investigate this new treatment. The Phase I safety results will be presented at the European Cancer Congress 2013 in Amsterdam at the end of September.
29 September, 2013
Creation of dedicated discovery unit at AblynxDiscovery and development of Nanobodies® against multiple targets in Merck Serono’s core therapeutic areas
28 September, 2013
Imperial Innovations Group plc, a leading technology commercialisation and investment group, announces that portfolio company Cell Medica, a leading T cell therapeutics company, has opened a European manufacturing facility in Berlin-Buch, Germany.
27 September, 2013
By Adrian Tombling, partner and patent attorney at Withers & Rogers (www.withersrogers.com).Just 18 months after a controversial patent ruling in the US, global pharmaceutical companies and manufacturers of diagnostic methods are working hard to overcome some of the nonsensical exclusions that now apply when seeking commercial protection there.
26 September, 2013
Aberdeen scientists are investigating if antibodies found naturally in sharks could be used to target breast cancer.
26 September, 2013
Scientists have discovered a natural temperature sensor in one of the bacteria that cause meningitis and blood poisoning, which allows them to evade the body’s immune response leading to life-threatening infections.
25 September, 2013
Medicinal chemistry as a discipline has contributed enormously to gains in public health over the past century.
24 September, 2013
A sub-analysis of results from the GetGoal-L study shows that Lyxumia® added to basal insulin lowered blood sugar (HbA1c) especially when fasting glucose was controlled
24 September, 2013
New York Academy of Sciences, in partnership with The Global CEO Initiative on Alzheimer’s Disease and the National Institute on Aging/NIH, to Launch “Path to 2025” Biennial Summit to Drive Progress in Alzheimer’s R&D over Next Decade
24 September, 2013
Cellectricon, a leading provider of advanced cell-based screening technologies and services, has announced the two winners of its Cellaxess® ACE project grant, supporting cutting-edge research in cell biology.
23 September, 2013
Molecular Profiles, one of The University of Nottingham’s longest established spin-out businesses, has been purchased by Columbia Laboratories, Inc. (Nasdaq: CBRX) of Boston, for approximately $25m (£16m).Molecular Profiles was established in 1997 by an academic group at The University of Nottingham’s School of Pharmacy, who identified an opportunity to deliver sophisticated analytical and development solutions to meet the growing needs of the pharmaceutical industry.
22 September, 2013
Initial space reservations place the new event well ahead of expectations.Industry support is growing for Pharma EXPO, the new pharmaceutical industry event from PMMI, The Association for Packaging and Processing Technologies, and the International Society for Pharmaceutical Engineering (ISPE). PMMI, the owner and producer of the PACK EXPO family of trade shows, announces a new partnership with Ipack-Ima Spa, which produces Pharmintech.
21 September, 2013
A new survey has found that four in five adults want the NHS to offer levels of access to treatment at least comparable with other countries. Half believe the NHS should be a world leader in the treatments available to patients and should pay for all treatments regardless of how much they cost, going beyond international standard practice
20 September, 2013
Findings from a published double-blind, placebo-controlled, randomised clinical trial designed to assess the efficacy and safety of varenicline compared with placebo in patients with a history of MDD*
19 September, 2013
ClinTec International, the global Clinical Research Organisation has been named as a finalist for the accolade of ‘Best CRO’ at the SCRIP Awards 2013, to be held in London’s Lancaster Hotel on November 21st, 2013. Being on the final shortlist for this accolade, at what is one of the biggest ceremonies in the pharmaceutical industry, marks a further landmark in what has been a successful year for the company.
19 September, 2013
The Royal Society of Chemistry (RSC) is bringing together leading scientists, technical experts and two of science’s most famous names, in a special free-to-attend conference at easyFairs LAB INNOVATIONS on 6 &7 November 2013 at Birmingham’s NEC.
18 September, 2013
Who decides which diseases to treat?
17 September, 2013
A type of gene therapy heralded as a potentially revolutionary treatment for a severe form of muscular dystrophy was treated with scepticism by major medical funding establishments, and was mostly funded through its earliest development by patient groups.
17 September, 2013
Cancer Research Technology Ltd. (CRT), Cancer Research UK’s technology development arm, and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have signed a multi-project alliance agreement to research and develop first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells.
16 September, 2013
Worldwide hearing implant leader MED-EL Medical Electronics today announced that its Founder and CEO Ingeborg Hochmair, PhD, has been selected to receive this year's prestigious Lasker-DeBakey Clinical Medical Research Award for the development of the modern cochlear implant, a device that restores hearing to individuals with severe-to-profound deafness through electrical stimulation of the auditory nerve. She will share the award with Graeme M. Clark (Emeritus, Univ. of Melbourne, Australia) and Blake S. Wilson (Duke University, NC, USA). This highly-respected scientific award honors scientists whose contributions have improved the clinical treatment of patients. The award ceremony will take place in New York City on Friday, September 20, 2013
15 September, 2013
Moreinx DuecomplusA’s project seeks Euros 1 million for DUE-C100 AML candidate
14 September, 2013
Domainex Ltd., a drug discovery company specialising in translational research support, has announced that the recipient of its first Discovery STAR Award; Professor Vilmos Fulop of the University of Warwick. This award will give Professor Fulop access to Domainex’s outstanding drug discovery capabilities to support his research for a much-needed new treatment for Chagas disease- a potentially life-threatening disease.
13 September, 2013
Significant milestone achieved in clinical development of ground breaking new cancer drug, ALM201and academic-industrial partnership to create new drug discovery unit
12 September, 2013
The latest issue of Drug Discovery Today is packed full of industry focused research articles, new developments in drug discovery, and expert comment and opinion.
11 September, 2013
Zealand Pharma has announced an exclusive peptide drug research and development collaboration agreement with Eli Lilly and Company (“Lilly”).
10 September, 2013
Reed Elsevier has announced the winners of the 2013 Reed Elsevier Environmental Challenge, which supports innovative solutions to improve sustainable access to safe water and sanitation.
09 September, 2013
Complex human brain tissue has been successfully developed in a three-dimensional culture system established in an Austrian laboratory.
06 September, 2013
Researchers at the University of Leuven (KU Leuven) are joining forces with Janssen Pharmaceuticals Inc. (Janssen) and the Wellcome Trust to discover and develop candidate antiviral drugs for the prevention and treatment of dengue infection.
03 September, 2013